Regulatory

Mar 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In the drug safety debate, we're hearing plenty of potential solutions. They're smart and advance desirable goals. There's just one thing wrong with them: They don't solve the problem.
Mar 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
If the Aspen model works, it could change the model for the developing world. Research-based companies could focus on R&D, and leave the manufacturing to generic companies.
Mar 01, 2005
Pharmaceutical Executive
Pharma companies in Europe believe that it already takes too long for new medicines to reach patients. Separate bodies for efficacy and safety will lead to further delays.
Feb 01, 2005
Pharmaceutical Executive
One response to today's safety concerns is particularly alarming: The research community has become skittish about conducting clinical studies involving pain medications and other high-risk treatments.
Feb 01, 2005
Pharmaceutical Executive
For companies that are prepared, Part D represents a great opportunity. For others, failing to react quickly enough could be a costly mistake.
native1_300x100
lorem ipsum